Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen
Open Access
- 9 June 2005
- Vol. 104 (2) , 345-353
- https://doi.org/10.1002/cncr.21151
Abstract
BACKGROUND Myelosuppression and immunosuppression occur with purine analogs. The objective of the current study was to investigate the effects of combined fludarabine, mitoxantrone, and dexamethasone (FND) followed by interferon/dexamethasone on myelosuppression (absolute neutrophil counts), immunosuppression (CD4 and CD8 counts), and infectious complications in patients with previously untreated, Stage IV indolent lymphoma. METHODS Seventy‐three patients were treated. All patients received Pneumocystis carinii pneumonia (PCP) prophylaxis. CD4 and CD8 counts, serum immunoglobulin (Ig) levels, and neutrophil counts were correlated with infectious complications. RESULTS The median follow‐up was 6.1 years. Sixty of 73 patients had CD4, CD8, or Ig measurements. The median baseline CD4 count was 764/μL: This CD4 level decreased to 238/μL at 1 year and to 264/μL at 2 years; and it rose to 431/μL by 3 years and to 650/μL at 4 years. CD8 counts did not change significantly. The median baseline serum IgG level was 989 mg/d, decreased to 536 mg/dL at 1 year and to 693 mg/dL at 2 years, and it rose to 949 mg/dL at 3 years and to 1080 mg/dL at 4 years. Fourteen patients (19%) developed Grade 3–4 infections, the majority during FND therapy with neutropenia and/or accompanied by CD4 counts < 200/μL. CD4, CD8, and neutrophil counts did not differ between patients who developed Grade 3–4 infections, Grade 1–2 infections, or no infections. CONCLUSIONS Most infections with FND occurred during FND, in the setting of neutropenia, often with concurrent low CD4 counts. The overall safety profile for FND was good. However, patients should be monitored for opportunistic infections, and prophylactic antibiotics are recommended, particularly against PCP. Cancer 2005. © 2005 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemiaCancer, 2004
- Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphomaBlood, 2002
- Fludarabine and mitoxantrone: Effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disordersAnnals of Oncology, 2001
- Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2001
- Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Infection and Immunity in Chronic Lymphocytic LeukemiaMayo Clinic Proceedings, 2000
- Trimethoprim-Sulfamethoxazole Salvage for Refractory Listeriosis During Maintenance Chemotherapy for Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 2000
- Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemiaThe Lancet, 1996
- Opportunistic pulmonary infections with fludarabine in previously treated patients with low‐grade lymphoid malignancies: A role for pneumocystis carinii pneumonia prophylaxisAmerican Journal of Hematology, 1995